Medical News

RSS

Cardiovascular Systems included in latest Russell 2000 Index

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, has been added to the Russell 2000® Index.

27 Jun 2011

Acorda to move corporate headquarters to Ardsley Park life science campus

Acorda Therapeutics, Inc. today announced that it plans to relocate its corporate headquarters to the Ardsley Park life science campus in Ardsley, New York, which was acquired by BioMed Realty Trust, Inc..

27 Jun 2011

Rogue super-activated neutrophils may cause organ damage in parts unconnected to injury

A study from scientists at Queen Mary, University of London, sheds new light on why people who experience serious trauma or go through major surgery, can suffer organ damage in parts of the body which are seemingly unconnected to the injury.

27 Jun 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

FDA responds to EpiCept Ceplene SPA

EpiCept Corporation today announced that it has received initial written responses from the U.S. Food and Drug Administration regarding the Company's application for a Special Protocol Assessment (SPA) of the Ceplene (histamine dihydrochloride) Phase III protocol.

27 Jun 2011

Redefinition of cardiac hypertrophy term needed

The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred.

27 Jun 2011

Centric Health to acquire DNPI Group assets

Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into a definitive asset purchase agreement through a wholly owned subsidiary to acquire certain assets of Dedicated National Pharmacies Inc., Methadrug Clinic Limited and Union Medical Pharmacy Inc. from the court-appointed receiver of the DNPI Group, Grant Thornton Limited (the "Receiver").

27 Jun 2011

Chaos in biochemical alterations of cancer cells

Using the latest gene sequencing tools to examine so-called epigenetic influences on the DNA makeup of colon cancer, a Johns Hopkins team says its results suggest cancer treatment might eventually be more tolerable and successful if therapies could focus on helping cancer cells get back to normal in addition to strategies for killing them.

27 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Endo recalls two lots of Endocet Tablets

Endo Pharmaceuticals today issued a voluntary nationwide consumer level recall of Endocet (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg 100 count bottles, NDC 60951-712-70, Lot # 402415NV and #402426NV.

27 Jun 2011

Metropolitan enters definitive merger agreement to acquire Continucare

Metropolitan Health Networks, Inc. and Continucare Corporation announced jointly today that they have entered into a definitive merger agreement whereby Metropolitan will acquire Continucare in a cash and stock transaction valued at approximately $416 million at the time of announcement.

27 Jun 2011

Teleflex, Premier sign new three-year agreement for laryngoscopes

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced a new three-year agreement with Premier Purchasing Partners, L.P., the group purchasing unit of the Premier healthcare alliance.

27 Jun 2011

Youngevity to acquire Bellamora

Youngevity Essential Life Sciences, which sells an extensive line of nutritional supplements and health and personal care products, announced today that it has signed a definitive agreement to acquire the distributor base and product line of Bellamora, a Tampa, Florida-based marketer of skin care products.

27 Jun 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

Spectranetics initiates enrollment in EXCITE clinical trial against femoropopliteal IRS

Spectranetics Corporation today announces the first patient enrollment in the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) clinical trial.

27 Jun 2011

First Edition: June 27, 2011

Today's headlines include reports about the status of ongoing deficit negotiations and details about a "stealth" survey on access to doctors.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

BD receives CEO Cancer Gold Standard accreditation

BD has received CEO Cancer Gold Standard accreditation, recognizing the company's commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for its own employees and their covered family members.

From BD (Becton, Dickinson and Company) 27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Derma Sciences announces $29 million financing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has closed its previously announced private placement.

27 Jun 2011